康柏西普与雷珠单抗对湿性年龄相关性黄斑变性患者视力及黄斑中心凹视网膜厚度的影响

Effect of Conbercept and Ranibizumab on Visual Acuity and Macular Foveal Retinal Thickness in Patients with Wet Age-related Macular Degeneration

目的:探讨康柏西普与雷珠单抗对湿性年龄相关性黄斑变性患者视力及黄斑中心凹视网膜厚度的影响。方法:选取2019年4月-2020年11月新余市人民医院收治的80例湿性年龄相关性黄斑变性患者,按照随机数字表法将患者分为康柏西普组(40只眼)给予康柏西普治疗和雷珠单抗组(40只眼)给予雷珠单抗治疗。比较两组裸眼视力、黄斑中心凹视网膜厚度、脉络膜新生血管面积及并发症情况。结果:治疗1周和治疗1、3个月后,两组黄斑中心凹视网膜厚度和脉络膜新生血管面积均低于治疗前,差异均有统计学意义(P<0.05)。治疗1周和治疗1、3个月后,两组黄斑中心凹视网膜厚度和脉络膜新生血管面积比较,差异均无统计学意义(P>0.05)。治疗1周和治疗1、3个月后,两组裸眼视力均优于治疗前,且雷珠单抗组均优于康柏西普组,差异均有统计学意义(P<0.05)。两组并发症发生率比较,差异无统计学意义(P>0.05)。结论:湿性年龄相关性黄斑变性患者应用康柏西普和雷珠单抗治疗可以显著改善裸眼视力和黄斑中心凹视网膜厚度,减少脉络膜新生血管面积,且具有较高安全性。

Objective:To investigate the effect of Conbercept and Ranibizumab on visual acuity and macular foveal retinal thickness in patients with wet age-related macular degeneration.Method:A total of 80 patients with wet age-related macular degeneration admitted to Xinyu People’s Hospital from April 2019 to November 2020 were selected,according to the random number table method,the patients were divided into the Conbercept group (40 eyes) received Conbercept treatment and the Ranibizumab group (40 eyes) received Ranibizumab treatment.The uncorrected visual acuity,macular foveal retinal thickness,choroidal neovascularization area and complications were compared between the two groups.Result:After 1 week,1 month and 3 months of treatment,the macular foveal retinal thickness and choroidal neovascularization area in both groups were lower than those before treatment,the differences were statistically significant (P<0.05).There were no significant difference in macular foveal retinal thickness and choroidal neovascularization area between the two groups at 1 week,1 month and 3 months after treatment (P>0.05).After 1 week,1 month and 3 months of treatment,the uncorrected visual acuity in both groups were better than those before treatment,those in the Ranibizumab group were better than the those in the Conbercept group,the differences were statistically significant (P<0.05).There was no significant difference in the incidence of complications between the two groups (P>0.05).Conclusion:Treatment with Conbercept and Ranibizumab in wet age-related macular degeneration can significantly improve uncorrected visual acuity and macular foveal retinal thickness,reduce the choroidal neovascularization area,and has high safety.